Tag: Breast Cancer

March 16, 2022 Off

Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer

By Dino Mustafić

Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.

May 7, 2020 Off

Canbridge gets marketing approval of Nerlynx in China

By BusinessWire

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner CANbridge Pharmaceuticals, Inc. has received marketing approval of NERLYNX® (neratinib) in mainland China from the National Medical Products Administration (NMPA) of China.